Ready to Use Biosimilar Cell Lines

You do not want to wait until you have your desired biosimilar cell line in hands? UGA Biopharma promote a broad spectrum of Ready to Use Biosimilar Cell Lines including documentation which are ready to out-license to a collaboration partner. In addition UGA Biopharma can accelerate your way to success by providing an optimized bioprocess, downstream process and analytical data and methods.

Ready To Use Biosimilar Cell Lines read more

Adalimumab (Humira^®) show description

Full package ready for sales now:

Research Cell Bank (RCB) including safety testing

Optimized fermentation process (USP)

Optimized downstream purification process (DSP) and analytics

Including proof of activity of the expressed protein

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Aflibercept (Zaltrap^®) show description

Aflibercept (Zaltrap^®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Anakinra (Kineret^®) show description

If you have any further question about the licensing conditions, please do not hesitate to contact us via: info@ugabiopharma.com

Bevacizumab (Avastin^®) show description

Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Certolizumab (Cimzia^®) show description

If you have any further question about the licensing conditions, please do not hesitate to contact us via: info@ugabiopharma.com

Darbepoetin alfa (Aranesp^®) show description

Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the Aranesp^® originator.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Dupilumab (Dupixent^®) show description

A outstanding product concentration higher than 7 g/L could be reached during the Dupilumab development project! The first CHOice^® Medium works very well for Dupilumab clones.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Eculizumab (Soliris^®) show description

Very good biosimilarity achieved in a challenging Eculizumab development project (IgG2/4 hybrid antibody).

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Etanercept (Enbrel^®) show description

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Ipilimumab (Yervoy^®) show description

Typical charge profil of Yervoy^®.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Laronidase (Aldurazyme^®) show description

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Natalizumab (Tysabri^®) show description

The primary structure of a biosimilar has to be identical to the originator molecule. The result of the peptide mapping of the Natalizumab biosimilar is depicted here.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Nivolumab (Opdivo^®) show description

A product concentration over 3 g/L has been obtained during a Nivolumab consistency run in stirred bioreactors.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Omalizumab (Xolair^®) show description

A product concentration of 3 g/L has been obtained during the Omalizumab biosimilar development project.

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Pembrolizumab (Keytruda^®) show description

Pembrolizumab (IgG4) biosimilar development project has been finalized in a very short time line – according to the High Speed Workflow of UGA Biopharma!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Pertuzumab (Perjeta^®) show description

Outstanding productivity higher than 5 g/L reached during the pertuzumab development project!

If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com

Vedolizumab Pools (Entyvio^®) show description

Pool stage finalized. On request, stable Vedolizumab clones can be developed within weeks!